View Prescriber Webcast

Drug Conviction Data in KASPER: What is a Prescriber to Do?

Activity Details
  • Credit Amounts:
    • CME: 1.50
    • Other: 1.50
    • CDE: 1.50
    • AANP: 1.50
  • Cost: Free
  • Release: Jan 15, 2020
  • Expires: Jan 14, 2023
  • Estimated Time to Complete:
    1 Hour(s)  30 Minutes
  • System Requirements:
  • Average User Rating:
    (44 Ratings)

Faculty

Patricia R.  Freeman Patricia R. Freeman, RPh, PhD, FAPhA
Associate Professor, Pharmacy Practice and Science
Director, Center for the Advancement of Pharmacy Practice (CAPP)
Faculty Associate, Institute for Pharmaceutical Outcomes and Policy (IPOP)
University of Kentucky College of Pharmacy
Lexington, Kentucky

Michelle R.  Lofwall Michelle R. Lofwall, MD, DFASAM
Professor, Psychiatry and Behavioral Science
Center on Drug and Alcohol Research
University of Kentucky College of Medicine
Bell Alcohol and Addictions Chair and Medical Director
First Bridge Clinic
UK HealthCare
Lexington, Kentucky

Dana L.  Quesinberry Dana L. Quesinberry, JD, DrPH
Assistant Professor, Health Management and Policy
University of Kentucky College of Public Health
Research Core Director
Kentucky Injury Prevention and Research Center
Lexington, Kentucky

Needs Statement

Kentucky State Senate Bill 32 (2017) mandated that drug conviction data be made available in KASPER effective July 1, 2018.  Education to prescribers on how to interpret this data in the context of patient care and opioid prescribing is needed to prevent unintended consequences.

Target Audience

This activity is designed for prescribers of controlled substances including physicians, nurse practitioners, dentists, and any other interested healthcare professionals.

Objectives

Kentucky Senate Bill 32 and Drug Conviction Data in KASPER: What Have We Learned?
Upon completion of this education activity, participants will be able to:

  • Discuss implications of SB 32 that made drug conviction data available in KASPER effective July 1, 2018
  • Review results of Kentucky prescriber and dispenser survey on intent to use drug conviction data in KASPER
  • Assess current data regarding the use of drug conviction data in KASPER by prescribers and dispensers 

Drug Conviction Data in KASPER: What Does it Mean?
Upon completion of this education activity, participants will be able to:

  • Describe the types of drug-related charges in Kentucky
  • Review example drug conviction data and describe its content and interpretation
  • Identify limitations of drug conviction data
  • Evaluate nuances of interpreting drug conviction data and legal implications

Drug Conviction Data in KASPER: What Should I Do?
Upon completion of this education activity, participants will be able to:

  • Discuss the impact of criminal conviction data on prescribers’ attitudes and resulting patient health outcomes
  • Use example vignettes to interpret drug conviction data in the context of patient care
  • Identify strategies for making sound decisions when prescribing controlled substances to prevent unintended consequences

Accreditation

CME
The University of Kentucky College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Kentucky College of Medicine designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The University of Kentucky College of Medicine presents this activity for educational purposes only. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the presentations is provided solely by presenters who have been selected for presentations because of recognized expertise in their field.

This training has been approved by the KBML as meeting the statutory requirements of HB1. 0120-H1.5-UK20b

ACGME Competencies

  • Patient care
  • Medical knowledge

Other
UK Healthcare CECentral certifies this activity for 1.50 hours of participation.

CDE
This online course meets regulatory requirements for 1.50 hours credit as permitted by 201 KAR 8:532 for dentists and 201 KAR 8:562 for dental hygienists.

AANP

AANP This activity is approved for 1.50 contact hours of continuing education (which includes 1.33 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 20014112.

This activity was planned in accordance with AANP Accreditation Standards and Policies.

Faculty Disclosure

Michelle Lofwall, MD (Speaker) has relevant financial relationships with commercial interests as follows:
Camurus - Speaker - Honorarium
Titan Pharmaceuticals, Inc. - Consultant - Consultant Fee

No other speakers, planners, or content reviewers have any relevant financial relationships to disclose. 

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Acknowledgment

This project was supported by Grant No. 2017-PM-BX-K026 (Data-Driven Responses to Prescription Drug Misuse in Kentucky) awarded by the Bureau of Justice Assistance (BJA) to the Kentucky Injury Prevention and Research Center as bona fide agent for the Kentucky Department for Public Health.

The BJA is a component of the Department of Justice’s Office of Justice Program, which includes the Bureau of Justice Statistics, the National Institute of Justice, the Office of Juvenile Justice and Delinquency Prevention, the Office of Victims Crime, and the SMART Office.

Viewpoints or opinions in these programs are those of the authors and do not necessarily represent the official position or policies of the US Department of Justice.

AANP Accreditation

This activity is approved for 1.83 contact hour(s) of continuing education (which includes 1.33 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 20014112. This activity was planned in accordance with AANP Accreditation Standards and Policies.

CE Content Concerns

Policy

Concerns or complaints related to ACPE or ACCME standards may be submitted in writing to the Director of UK HealthCare CECentral by fax to 859-323-2920, or by mail to 2365 Harrodsburg Road, Ste B475, Lexington, KY 40504

Procedures

  • The Director or his/her designee will review, investigate, forward and/or respond to complaints and will put forth a best effort to adjudicate the issue(s), along with CECentral staff members, within two (2) weeks of receipt of the grievance or complaint.
  • If needed, concerns, complaints, or grievances will be brought before the UK HealthCare CECentral Advisory Board.
  • Issues regarding activity content also will be reviewed and addressed by the Activity Director.
  • A written decision will be issued in a timely manner by the Director of UK HealthCare CECentral or his/herdesignee.
  • Grievances will be considered when planning future activities.

Appeal Procedure

  • Persons who wish to appeal a decision should address the appeal by email, fax or in writing to the Director of UK HealthCare CECentral within two (2) weeks of receipt of the response.
  • The Director will bring the appeal to the UK HealthCare CECentral Advisory Board.
  • The results of the appeal will be sent to the participant no later than two (2) weeks following the meeting of the board.